78967-07-4

Basic information

• Product Name: Mofezolac
• Synonyms: Mofezolac;3,4-Bis(4-methoxyphenyl)isoxazole-5-acetic acid;Disopain;N-22;α-[3,4-Bis(4-methoxyphenyl)-5-isoxazolyl]acetic acid;2-(3,4-bis(4-Methoxyphenyl)isoxazol-5-yl)acetic acid;3,4-Bis(4-methoxyphenyl)-5-isoxazoleacetic acid
• CAS NO: 78967-07-4
• Molecular Formula: C₁₉H₁₇NO₅
• Molecular Weight: 339.345
• Mol File: 78967-07-4.mol
• Article Data: 4

Chemical Properties

• Melting Point: 147.5℃
• Boiling Point: 527.2°C at 760 mmHg
• Flash Point: 272.7°C
• Appearance: /
• Density: 1.25g/cm³
• Vapor Pressure: 6.04E-12mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: 2-8°C
• PKA: pKa ~3.3(at 25℃)
• CAS DataBase Reference: Mofezolac(CAS DataBase Reference)
• NIST Chemistry Reference: Mofezolac(78967-07-4)
• EPA Substance Registry System: Mofezolac(78967-07-4)

Safety Data

• Hazardous Substances Data: 78967-07-4(Hazardous Substances Data)

Usage

Description

Mofezolac, also known as Disopain, is a non-steroidal analgesic anti-inflammatory agent (NSAID) that was introduced in Japan. It is primarily used for the treatment of various types of pain, including post-operative and post-traumatic pain, acute upper respiratory tract pain, osteoarthritis, and lumbago. Mofezolac works by inhibiting prostaglandin biosynthesis and platelet aggregation, which is achieved through the inhibition of cyclooxygenase. In in vitro studies, it has demonstrated more potent suppression in various pain models compared to other agents such as ibuprofen, mefenamic acid, and aspirin. Additionally, Mofezolac has a potent inhibitory activity on the algesic responses induced by the mechanical stimulus of inflamed tissue. It is also noteworthy that the ulcerogenic effect of Mofezolac on the gastric mucosa is significantly weaker than that of other NSAIDs, such as indomethacin.

Uses

Used in Pharmaceutical Industry:
Mofezolac is used as an analgesic and anti-inflammatory agent for the treatment of various types of pain, including post-operative and post-traumatic pain, acute upper respiratory tract pain, osteoarthritis, and lumbago. Its application is based on its ability to inhibit prostaglandin biosynthesis and platelet aggregation, as well as its potent suppression in various pain models and inhibitory activity on algesic responses induced by the mechanical stimulus of inflamed tissue.
Used in Pain Management:
Mofezolac is used as a pain management agent for patients experiencing pain due to various conditions, such as post-operative and post-traumatic pain, acute upper respiratory tract pain, osteoarthritis, and lumbago. Its effectiveness in pain management is attributed to its ability to inhibit prostaglandin biosynthesis and platelet aggregation, as well as its potent suppression in various pain models and inhibitory activity on algesic responses induced by the mechanical stimulus of inflamed tissue.
Used in Inflammation Reduction:
Mofezolac is used as an anti-inflammatory agent to reduce inflammation associated with various conditions, such as osteoarthritis and lumbago. Its anti-inflammatory properties are due to its ability to inhibit prostaglandin biosynthesis and platelet aggregation, which are key factors in the inflammatory process.
Used in Gastrointestinal Protection:
Mofezolac is used as a gastrointestinal protective agent due to its significantly weaker ulcerogenic effect on the gastric mucosa compared to other NSAIDs, such as indomethacin. This makes it a preferred choice for patients who require pain relief and anti-inflammatory treatment but are at risk of developing gastrointestinal side effects from other NSAIDs.

Originator

Pasteur Merieux (France)

InChI:InChI=1/C19H17NO5/c1-23-14-7-3-12(4-8-14)18-16(11-17(21)22)25-20-19(18)13-5-9-15(24-2)10-6-13/h3-10H,11H2,1-2H3,(H,21,22)

Upstream product

• 124-38-9 carbon dioxide 
• 122-84-9 4-methoxybenzyl methyl ketone 
• 15500-73-9 4-methoxybenzonitrile oxide 
• 109-72-8 n-butyllithium 
• 131454-49-4 5-methoxycarbonylmethyl-3,4-bis(4-methoxyphenyl)isoxazole 

Downstream Products

• 1620743-21-6 3,4-bis(4-methoxyphenyl)-5-vinylisoxazole 
• 1620743-20-5 2-[3,4-bis(4-methoxyphenyl)isoxazol-5-yl]ethyl 4-methylbenzenesulfonate 

Relevant articles and documents

Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability

A set of novel diarylisoxazoles has been projected using mofezolac (1) as a lead compound to investigate structure-inhibitory activity relationships of new compounds and the cyclooxygenases (COXs) catalytic activity. Mofezolac was chosen because is the mo

α, β-unsaturated ketones and ketoxime derivatives

The present invention provides an α, β-unsaturated ketone and ketoxime derivative represented by the formula STR1 wherein Y is oxygen atom or hydroxyimino group, Z is cyano or alkoxycarbonyl group, R1 and R2 are the same or different